Drug Name: Elrexfio
Indications: To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.
Active Ingredient: Elranatamab-bcmm
Company: Pfizer Inc
Approval Date: 8/14/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf